From The Economic Times · Snehal Mergu · · 1m 30s
Pharma Q2 Outlook: Pricing Pressure and US Competition
India's pharma giants face mixed Q2 results as pricing pressures and US competition reshape their outlook.
In brief
India's pharma giants face mixed Q2 results as pricing pressures and US competition reshape their outlook. India's pharmaceutical companies report mixed Q2 performance with domestic growth offsetting pricing pressures and US competition. Originally reported by The Economic Times.
Q2 Performance Forecast
India's pharmaceutical companies report mixed Q2 results with domestic growth offsetting pricing pressures and US competition.
Strong Performers
Sun Pharmaceutical Industries, Aurobindo Pharma, Torrent Pharmaceuticals and Divi's Laboratories are expected to be among the stronger performers.
Pressure Points
Dr Reddy's Laboratories, Lupin and Cipla may face pressure due to absent high-margin opportunities and increased competition in key products.
Sun Pharma Growth
Sun Pharma expects high-single-digit revenue growth from India, emerging markets and specialty products like Leqselvi, Unloxcyt, and Winlevi.
Aurobindo Pharma
Aurobindo Pharma's revenue growth is led by Lannett acquisition, strong European performance and stable US business with double-digit EBITDA growth.
Dr Reddy's Challenges
Dr Reddy's revenue remains flat as North America weakness offsets growth in other markets, with key monitorables including semaglutide supply restoration.
Lupin and Cipla
Lupin expects high-single-digit revenue growth from India and non-US markets, while Cipla faces flat revenue despite strong Indian growth due to US business challenges.
Torrent Pharma
Torrent Pharma's revenue growth is strongest among peers following JB Pharma consolidation with healthy core business growth in India and US.
Divi's Laboratories
Divi's Laboratories' revenue driven by custom synthesis business, nutraceuticals growth, and iodine-based contrast media scale-up.
The bottom line
India's pharmaceutical companies report mixed Q2 performance with domestic growth offsetting pricing pressures and US competition.
